���ѵ���

With a family history of mental illness and addiction, I was long aware the these psychiatric disorders emerge at the interface of biological, social, psychological, and psychospiritual dimensions of experience. For that reason, I became interested in psychedelic-assisted therapy research, given early data suggesting that psychedelic treatments might address clinical concerns in a holistic way.

I have been involved in psychedelic research at NYU Langone since 2016, and I am now an Assistant Professor of Psychiatry and the Director of Clinical Training at the NYU Langone Center for Psychedelic Medicine. Led by other faculty at the NYU Langone Center for Psychedelic Medicine, studies I've been involved with include psychedelic-assisted therapy for alcohol use disorder, major depressive disorder, post-traumatic stress disorder, smoking cessation, and cancer-associated anxiety and distress, as well as upcoming trials of psychedelic-assisted therapy for opioid use disorder and post-partum depression. On these studies, I have worked as a psychedelic therapist, co-investigator, study physician, trainer, clinical supervisor, and adherence rater. In addition to these clinical trials, I am also involved in psychedelic curriculum development initiatives for medical students, residents, and other trainees.